Compare Booz Allen Hamilton Holding Corporation (BAH) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs ClearPoint Neuro Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $76.91 (market cap $9.45B), while ClearPoint Neuro Inc trades at $14.57 (market cap $454.21M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 20.8× ClearPoint Neuro Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| BAH | CLPT | |
|---|---|---|
Market Cap | $9.45B | $454.21M |
Sector | Industrials | Health |
52-Week High | $111.63 | $29.60 |
52-Week Low | $59.71 | $8.66 |
Enterprise Value | $13.07B | $488.79M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.9, up 2.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 7.01% net margin and 68.11% ROE, supported by $11.98B revenue in 2025. Analysts maintain a Buy consensus with a $84.67 price target, citing government contracts and AI investments as growth drivers, though debt levels and civil revenue weakness pose concerns.
The outlook for BAH is positive due to consistent earnings outperformance and strategic focus on national security and cybersecurity. Investment appeal lies in its discounted valuation (P/E 12.33) and dividend yield, but risks include high leverage (debt-to-asset 54.67%) and reliance on government spending, which could impact growth if budget pressures arise.
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
